| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5741523 | PFIZER | Stabilized prostaglandin E1 |
Apr, 2015
(9 years ago) | |
Caverject is owned by Pfizer.
Caverject contains Alprostadil.
Caverject has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Caverject are:
- US5741523
Caverject was authorised for market use on 27 June, 1996.
Caverject is available in injectable;injection dosage forms.
The generics of Caverject are possible to be released after 21 April, 2015.
Drugs and Companies using ALPROSTADIL ingredient
Market Authorisation Date: 27 June, 1996
Treatment: NA
Dosage: INJECTABLE;INJECTION
More Information on Dosage
CAVERJECT family patents
